| The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease K Seppi, D Weintraub, M Coelho, S Perez‐Lloret, SH Fox, ... Movement disorders 26 (S3), S42-S80, 2011 | 1103 | 2011 |
| A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease A Zimprich, A Benet-Pagès, W Struhal, E Graf, SH Eck, MN Offman, ... The American Journal of Human Genetics 89 (1), 168-175, 2011 | 1060 | 2011 |
| International Parkinson and movement disorder society evidence‐based medicine review: update on treatments for the motor symptoms of Parkinson's disease SH Fox, R Katzenschlager, SY Lim, B Barton, RMA De Bie, K Seppi, ... Movement Disorders 33 (8), 1248-1266, 2018 | 841 | 2018 |
| The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease SH Fox, R Katzenschlager, SY Lim, B Ravina, K Seppi, M Coelho, ... Movement Disorders 26 (S3), S2-S41, 2011 | 825 | 2011 |
| Gait disorders in adults and the elderly: A clinical guide W Pirker, R Katzenschlager Wiener Klinische Wochenschrift 129 (3-4), 81-95, 2017 | 757 | 2017 |
| Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review K Seppi, K Ray Chaudhuri, M Coelho, SH Fox, R Katzenschlager, ... Movement Disorders 34 (2), 180-198, 2019 | 741 | 2019 |
| Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome AH Evans, R Katzenschlager, D Paviour, JD O'Sullivan, S Appel, ... Movement disorders: official journal of the Movement Disorder Society 19 (4 …, 2004 | 641 | 2004 |
| The O nset of N onmotor S ymptoms in P arkinson's disease (T he ONSET PD S tudy) C Pont‐Sunyer, A Hotter, C Gaig, K Seppi, Y Compta, R Katzenschlager, ... Movement Disorders 30 (2), 229-237, 2015 | 586 | 2015 |
| Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of P arkinson's disease JJ Ferreira, R Katzenschlager, BR Bloem, U Bonuccelli, D Burn, ... European journal of neurology 20 (1), 5-15, 2013 | 550 | 2013 |
| Levodopa in the treatment of Parkinson's disease: current controversies CW Olanow, Y Agid, Y Mizuno, A Albanese, U Bonucelli, P Damier, ... Movement disorders 19 (9), 997-1005, 2004 | 505 | 2004 |
| Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study R Katzenschlager, A Evans, A Manson, PN Patsalos, N Ratnaraj, H Watt, ... Journal of Neurology, Neurosurgery & Psychiatry 75 (12), 1672-1677, 2004 | 452 | 2004 |
| Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data NL Khan, S Jain, JM Lynch, N Pavese, P Abou-Sleiman, JL Holton, ... Brain 128 (12), 2786-2796, 2005 | 375 | 2005 |
| Anticholinergics for symptomatic management of Parkinson s disease R Katzenschlager, C Sampaio, J Costa, A Lees, ... Cochrane Database of Systematic Reviews 2010 (1), 1996 | 369 | 1996 |
| Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD R Katzenschlager, J Head, A Schrag, Y Ben-Shlomo, A Evans, AJ Lees Neurology 71 (7), 474-480, 2008 | 356 | 2008 |
| Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single‐dose challenges R Katzenschlager, A Hughes, A Evans, AJ Manson, M Hoffman, L Swinn, ... Movement disorders: official journal of the Movement Disorder Society 20 (2 …, 2005 | 327 | 2005 |
| Treatment of Parkinson's disease: levodopa as the first choice R Katzenschlager, AJ Lees Journal of neurology 249, ii19-ii24, 2002 | 304 | 2002 |
| Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled … R Katzenschlager, W Poewe, O Rascol, C Trenkwalder, G Deuschl, ... The Lancet Neurology 17 (9), 749-759, 2018 | 274 | 2018 |
| Euro I nf: AM ulticenter C omparative O bservational S tudy of A pomorphine and L evodopa I nfusion in P arkinson's D isease P Martinez‐Martin, P Reddy, R Katzenschlager, A Antonini, A Todorova, ... Movement Disorders 30 (4), 510-516, 2015 | 250 | 2015 |
| Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease E Wolf, K Seppi, R Katzenschlager, G Hochschorner, G Ransmayr, ... Movement Disorders 25 (10), 1357-1363, 2010 | 243 | 2010 |
| Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson’s disease AH Evans, AD Lawrence, J Potts, L MacGregor, R Katzenschlager, ... Journal of Neurology, Neurosurgery & Psychiatry 77 (3), 317-321, 2006 | 243 | 2006 |
